Key Highlights

  • SeaStar Medical (NASDAQ:ICU) rose 12.76% to USD 2.47, with a pivotal trial 223 of 339 patients enrolled.
  • Curanex Pharmaceuticals (NASDAQ:CURX) rose 13.37% to USD 5.85 on Volume of only 3.35K shares.
  • Neumora Therapeutics (NASDAQ:NMRA) rose 15.07% to USD 0.5704 after a Nasdaq bid-price notice.
  • CNS Pharmaceuticals (NASDAQ:CNSP) fell 12.20% to USD 4.39 on volume of 15.1K shares.
  • InspireMD (NASDAQ:NSPR) rose 13.21% to USD 0.6102 ahead of third quarter results on November 12, 2026.

SeaStar Medical (NASDAQ:ICU) (up USD 0.2795, 12.76%): Trial Enrollment in Focus

SeaStar Medical (NASDAQ:ICU) rose 12.76% to USD 2.47 in regular trading on November 3, 2026, from a prior close of about USD 2.19 (calculated), on volume of 1.73M shares. No company release or filing dated between October 30 and November 3 was identified, so no specific catalyst can be named.

Second quarter 2026 net Revenue was about USD 615 thousand, up roughly 82%, and the net loss was USD 3,730 thousand. The NEUTRALIZE-AKI trial had enrolled 223 of 339 patients. Cash was USD 6,959 thousand at June 30, 2026, down from USD 11,980 thousand at December 31, 2025. As a Penny Stock with quarterly cash burn near USD 3 million (calculated), further Capital raising is likely.

Curanex Pharmaceuticals (NASDAQ:CURX) (up USD 0.6899, 13.37%): A Micro-Cap After a Reverse Split

Curanex Pharmaceuticals (NASDAQ:CURX) rose 13.37% to USD 5.85 in regular trading on November 3, 2026, from about USD 5.1601 (calculated). Volume was only 3.35K shares, and no announcement dated November 2 or November 3 was identified. The gain appears to reflect thin trading after a 1-for-20 reverse split on August 20, 2026.

The company plans an IND submission for Phyto-N in ulcerative colitis in the fourth quarter of 2026. Cash was USD 2,938,463 at June 30, 2026, and management said existing cash does not fund operations for twelve months, raising Going Concern doubt. Any financing could dilute existing holders.

Neumora Therapeutics (NASDAQ:NMRA) (up USD 0.0747, 15.07%): A Bounce After a Listing Warning

Neumora Therapeutics (NASDAQ:NMRA) rose 15.07% to USD 0.5704 in regular trading on November 3, 2026, from about USD 0.4957 (calculated). The latest filing identified, signed October 30, 2026, disclosed a Nasdaq notice dated October 26 that the bid price was below USD 1.00, with a compliance deadline of April 26, 2027. No announcement dated November 2 or 3 was identified, so the gain may reflect a rebound.

Navacaprant development was discontinued after two Phase 3 studies missed their primary endpoints. Cash was USD 116.8 million at June 30, 2026, which the company said should fund its plan into the third quarter of 2027. As a penny stock, it faces dilution risk, and the company said it would consider Options including a reverse stock split.

CNS Pharmaceuticals (NASDAQ:CNSP) (down USD 0.6100, 12.20%): A Thin Pullback After a Funding Round

CNS Pharmaceuticals (NASDAQ:CNSP) was down 12.20% to USD 4.39 in regular trading on November 3, 2026, from about USD 5.00 (calculated). Volume was light at 15.1K shares, and no announcement dated between October 30 and November 3 was identified, so the move looks like a thin-liquidity pullback.

A private Placement closed on May 5, 2026 raised about USD 22.5 million gross, and cash was about USD 20.0 million at June 30, 2026. Management targets in-licensing or acquiring one or more Assets by December 31, 2026. As a penny stock with no marketed product, it carries Volatility and dilution risk, including from pre-funded warrants.

InspireMD (NASDAQ:NSPR) (up USD 0.0712, 13.21%): Bouncing Before Earnings

InspireMD (NASDAQ:NSPR) rose 13.21% to USD 0.6102 in regular trading on November 3, 2026, from about USD 0.539 (calculated), on volume of 199.03K shares. No release or filing dated between October 30 and November 3 was identified as a trigger. The most recent notice, dated October 29, 2026, set third quarter results for November 12, 2026.

A voluntary recall of the CGuard Prime 135 cm delivery system, announced May 1, 2026, led to withdrawn 2026 revenue guidance. Second quarter revenue was USD 1.771 million and the net loss was USD 14.324 million. Cash and marketable securities were USD 30.421 million at June 30, 2026. Filings list going concern doubt and a Nasdaq minimum bid price notice among the risks.

Where Things Stand

The five companies sit at different stages, from a commercial-stage device maker to clinical-stage developers, yet they share small market values, modest trading volume and balance sheets that depend on outside capital. Four rose and one fell, and for none was a fresh company announcement identified as the cause, so the moves may reflect thin Liquidity or rebounds.

Items to watch include the InspireMD results on November 12, 2026, SeaStar enrollment progress, the Curanex IND timing, Neumora bid-price compliance, and any asset deal at CNS. This article is informational only.